NCT05831098View on ClinicalTrials.gov

Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 12, 2023

Primary Completion Date

December 6, 2024

Study Completion Date

January 31, 2026

Conditions
Syphilis InfectionSyphilisEarly Syphilis, Symptomatic
Interventions
DEVICE

Reveal TP (Syphilis) Antibody Test

All subjects tested with both investigational devices and conventional syphilis serology tests.

Trial Locations (1)

V5Z 4R4

BCCDC STI Clinic, Vancouver

Sponsors
All Listed Sponsors
collaborator

Public Health Agency of Canada (PHAC)

OTHER_GOV

lead

MedMira Laboratories Inc.

INDUSTRY

NCT05831098 - Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT | Biotech Hunter | Biotech Hunter